The identification, evolution and clinical use of biomarkers in cardiovascular medicine, particularly in heart failure, have advanced dramatically over the past few decades. Progress in biomarker research related to cardiovascular disease has led to more sensitive screening methods, a greater emphasis on early detection and the establishment of clinical diagnoses, provided prognostic information and improved the ability to monitor the effectiveness of therapeutic interventions. Importantly, this has resulted in more favorable patient outcomes. However, the development of novel biomarkers to investigate physiologic and pathophysiologic processes in cardiovascular disease remains an important area of ongoing clinical research. Further, the reimaged use of established biomarkers is being explored with many new developments yet to come. While this area is vast in the scope of biomarkers that are currently being used or studied in the arena of cardiovascular medicine, this special issue in “Reviews in Cardiovascular Medicine” will focus on the prognostic and therapy-related monitoring roles of various key biomarkers and their incremental benefit and utility for clinical practice. We hope this discussion will provide our readers with new insights and affirm information on biomarkers and their use in cardiovascular medicine.
Prof. Wayne L. Miller
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- Performance Evaluation of AFIAS ST2 and Ichroma ST2 Assays in Comparison with Presage ST2 AssayHanah Kim, Tae-Hwan Lee, Mina Hur, Hyun-Joong Kim, ... Salvatore Di SommaRev. Cardiovasc. Med. 2023, 24(4), 100; https://doi.org/10.31083/j.rcm240410050Downloads187Views
- Sex-Specific Thresholds for Cardiac Biomarkers—We Need to Move ForwardRonstan Lobo, Allan S. JaffeRev. Cardiovasc. Med. 2023, 24(3), 86; https://doi.org/10.31083/j.rcm240308635Downloads143Views
- The Prognostic Value of Cardiac Biomarkers in Patients with Acute Myocardial Infarction during and after HospitalizationKarolina Idzikowska, Michal Kacprzak, Marzenna ZielinskaRev. Cardiovasc. Med. 2022, 23(9), 320; https://doi.org/10.31083/j.rcm230932054Downloads187Views
- Macrophage-Related Genes Biomarkers in Left Ventricular Remodeling Induced by Heart FailureYue Zheng, Yuheng Lang, Zhenchang Qi, Bingcai Qi, ... Tong LiRev. Cardiovasc. Med. 2022, 23(3), 109; https://doi.org/10.31083/j.rcm2303109149Downloads2Citations531Views
- Circulating microRNAs in the prediction of BAV aortopathy: do the expression patterns correlate between blood and aortic tissue?Shiho Naito, Tatiana Sequeira-Gross, Johannes Petersen, Inken Detlef, ... Evaldas GirdauskasRev. Cardiovasc. Med. 2022, 23(2), 47; https://doi.org/10.31083/j.rcm230204756Downloads2Citations293Views